iHuman
7 hedge funds and large institutions have $7.29M invested in iHuman in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.06% less ownership
Funds ownership: 2.77% → 2.71% (-0.06%)
9% less capital invested
Capital invested by funds: $8.02M → $7.29M (-$735K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$2.19K |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.16K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$194K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1.15K |
IH Hedge Fund Activity: Q3 2022 in Review
7 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in iHuman (IH) for Q3 2022, worth a combined $7.29M — down 9.2% from $8.02M a quarter earlier.
Fund positioning in IH was balanced in Q3 2022: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $2.19K. The largest seller was Morgan Stanley, cutting an estimated $194K.
- 7 institutional investors held iHuman (IH) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $7.29M of iHuman stock for Q3 2022, down 9.2% quarter-over-quarter.
- 1 fund opened new iHuman positions in Q3 2022 and 1 closed out, a net change of 0 holders.
- The largest iHuman buyer in Q3 2022 was BNP Paribas Financial Markets, an estimated $2.19K added.
- The largest iHuman seller in Q3 2022 was Morgan Stanley, an estimated $194K sold.
Based on aggregated 13F filings for Q3 2022.